[go: up one dir, main page]

WO2011025167A3 - 2, 6-위치가 치환된 3-니트로피리딘 유도체 화합물 또는 이의 약제학적으로 허용 가능한 염을 포함하는 암 예방 또는 치료용 약학 조성물 - Google Patents

2, 6-위치가 치환된 3-니트로피리딘 유도체 화합물 또는 이의 약제학적으로 허용 가능한 염을 포함하는 암 예방 또는 치료용 약학 조성물 Download PDF

Info

Publication number
WO2011025167A3
WO2011025167A3 PCT/KR2010/005336 KR2010005336W WO2011025167A3 WO 2011025167 A3 WO2011025167 A3 WO 2011025167A3 KR 2010005336 W KR2010005336 W KR 2010005336W WO 2011025167 A3 WO2011025167 A3 WO 2011025167A3
Authority
WO
WIPO (PCT)
Prior art keywords
preventing
pharmaceutical composition
treating cancer
substituted
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2010/005336
Other languages
English (en)
French (fr)
Other versions
WO2011025167A2 (ko
Inventor
한동초
권병목
윤영주
이진수
유제만
성승규
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Research Institute of Bioscience and Biotechnology KRIBB
Dong Wha Pharm Co Ltd
Original Assignee
Korea Research Institute of Bioscience and Biotechnology KRIBB
Dong Wha Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Research Institute of Bioscience and Biotechnology KRIBB, Dong Wha Pharm Co Ltd filed Critical Korea Research Institute of Bioscience and Biotechnology KRIBB
Publication of WO2011025167A2 publication Critical patent/WO2011025167A2/ko
Publication of WO2011025167A3 publication Critical patent/WO2011025167A3/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 2, 6-위치가 치환된 3-니트로피리딘 유도체 화합물 또는 이의 약제학적으로 허용 가능한 염을 포함하는 암 예방 또는 치료용 약학 조성물을 제공한다. 본 발명의 약학 조성물은 암세포주의 성장과 Heat shock factor 1의 활성을 효과적으로 저해함으로써 암 치료와 암 예방에 유용하게 사용될 수 있다.
PCT/KR2010/005336 2009-08-28 2010-08-13 2, 6-위치가 치환된 3-니트로피리딘 유도체 화합물 또는 이의 약제학적으로 허용 가능한 염을 포함하는 암 예방 또는 치료용 약학 조성물 Ceased WO2011025167A2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020090080742A KR101630432B1 (ko) 2009-08-28 2009-08-28 2, 6-위치가 치환된 3-니트로피리딘 유도체 화합물 또는 이의 약제학적으로 허용되는 염을 포함하는 암 예방 또는 치료용 약학 조성물
KR10-2009-0080742 2009-08-28

Publications (2)

Publication Number Publication Date
WO2011025167A2 WO2011025167A2 (ko) 2011-03-03
WO2011025167A3 true WO2011025167A3 (ko) 2011-06-16

Family

ID=43628541

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/005336 Ceased WO2011025167A2 (ko) 2009-08-28 2010-08-13 2, 6-위치가 치환된 3-니트로피리딘 유도체 화합물 또는 이의 약제학적으로 허용 가능한 염을 포함하는 암 예방 또는 치료용 약학 조성물

Country Status (2)

Country Link
KR (1) KR101630432B1 (ko)
WO (1) WO2011025167A2 (ko)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201317609D0 (en) 2013-10-04 2013-11-20 Cancer Rec Tech Ltd Inhibitor compounds
GB201505658D0 (en) 2015-04-01 2015-05-13 Cancer Rec Tech Ltd Inhibitor compounds
GB201617103D0 (en) 2016-10-07 2016-11-23 Cancer Research Technology Limited Compound
WO2020123675A1 (en) * 2018-12-11 2020-06-18 Duke University Compositions and methods for the treatment of cancer
US20220175812A1 (en) 2020-12-03 2022-06-09 Battelle Memorial Institute Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery
JP2024516108A (ja) 2021-04-07 2024-04-12 バテル・メモリアル・インスティテュート 非ウイルス性担体を同定および使用するための迅速な設計、構築、試験、および学習技術
KR102738668B1 (ko) * 2022-02-25 2024-12-06 계명대학교 산학협력단 항암 활성을 갖는 신규 화합물 및 이의 용도
CN115611885B (zh) * 2022-08-29 2024-07-19 厦门大学 N-取代-5-((4-取代嘧啶-2-基)氨基)-1h-吲哚-2-甲酰胺衍生物
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
US12441996B2 (en) 2023-12-08 2025-10-14 Battelle Memorial Institute Use of DNA origami nanostructures for molecular information based data storage systems
CN119798223B (zh) * 2025-01-02 2025-10-24 沈阳药科大学 一种(1h-吲唑-5-基)氨基-2-吡啶衍生物及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567272A (en) * 1983-09-21 1986-01-28 Rutgerswerke Aktiengesellschaft Pyrrole containing 2-aminonitropyridine derivatives
KR20090025371A (ko) * 2006-07-01 2009-03-10 메르크 파텐트 게엠베하 Ｈｓｐ90-유도 질병 치료용 인다졸 유도체

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100566194B1 (ko) * 1999-12-29 2006-03-29 동화약품공업주식회사 신규의 3-니트로피리딘 유도체 및 그를 포함하는 약학적조성물

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567272A (en) * 1983-09-21 1986-01-28 Rutgerswerke Aktiengesellschaft Pyrrole containing 2-aminonitropyridine derivatives
KR20090025371A (ko) * 2006-07-01 2009-03-10 메르크 파텐트 게엠베하 Ｈｓｐ90-유도 질병 치료용 인다졸 유도체

Also Published As

Publication number Publication date
KR101630432B1 (ko) 2016-06-15
KR20110023118A (ko) 2011-03-08
WO2011025167A2 (ko) 2011-03-03

Similar Documents

Publication Publication Date Title
WO2011025167A3 (ko) 2, 6-위치가 치환된 3-니트로피리딘 유도체 화합물 또는 이의 약제학적으로 허용 가능한 염을 포함하는 암 예방 또는 치료용 약학 조성물
WO2012047017A3 (ko) 2,3-디히드로-이소인돌-1-온 유도체 및 이를 포함하는 조성물
WO2010021680A3 (en) Inhibitors of beta-secretase
TR201906936T4 (tr) Protein kinaza yönelik inhibitör aktiviteye sahip tiyenopirimidin türevleri.
WO2010108074A3 (en) Inhibitors of pi3 kinase
WO2011093684A3 (en) THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES
TWI562992B (en) Indazole derivative, pharmaceutical composition thereof, and use thereof as inhibitors of kinase activity
WO2010088000A3 (en) Antifibrotic compounds and uses thereof
MX2012000414A (es) Derivados piridin-4-ilo.
WO2011014795A3 (en) Compounds and compositions as syk kinase inhibitors
WO2009071480A3 (en) Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors
IN2014KN00948A (ko)
SI2324008T1 (sl) 3,4-diarilpirazoli kot protein-kinazni inhibitorji
PH12013501594A1 (en) Substituted indazole derivatives active as kinase inhibitors
WO2012021796A3 (en) Novel cyclosporin derivatives for the treatment and prevention of a viral infection
TW200801000A (en) Spiroindolinone derivatives
TN2012000413A1 (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
MX2011011083A (es) Compuestos heterociclicos como inhibidores de mek.
WO2011052923A3 (en) Novel 1,6-disubstituted indole compounds as protein kinase inhibitors
WO2010016683A3 (ko) 탈모의 예방, 치료, 또는 육모용 조성물
CA2881554C (en) Methods for inhibiting fascin
RU2018135973A (ru) Фармацевтическая комбинация, содержащая метроформин и дигидрокверценин, и ее применение для лечения рака
MX341342B (es) Formas solidas del inhibidor de girasa (r)-1-etil-3-[6-fluoro-5-[2 -(1-hidroxi-1-metil-etil) pirimidin-5-il]-7-(tetrahidrofuran-2-il) -1h-benzimidazol-2-il]urea.
WO2009094560A3 (en) Thienopyranones as kinase inhibitors
EP2583962A4 (en) NOVEL THIOURED OR NEW UREA DERIVATIVE, PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING THE SAME AS ACTIVE INGREDIENT

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10812181

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10812181

Country of ref document: EP

Kind code of ref document: A2